A 68-year-old man with chronic kidney disease (eGFR 25 mL/min/1.73m²) is prescribed gentamicin 80 mg IV once daily for a urinary tract infection. His serum creatinine is 3.2 mg/dL. On day 3 of therapy, his serum gentamicin peak level is 12 µg/mL (therapeutic: 4–10 µg/mL) and trough is 2.5 µg/mL (therapeutic: <2 µg/mL). Which pharmacokinetic parameter is primarily responsible for the elevated peak and trough levels, and what is the most appropriate intervention?

Explanation

## Pharmacokinetic Basis of Drug Accumulation in Renal Failure **Key Point:** Gentamicin is an aminoglycoside that is eliminated almost entirely (>90%) by glomerular filtration. In chronic kidney disease with severely reduced GFR, renal clearance (CL~renal~) is dramatically decreased, leading to drug accumulation. ### Clearance and Steady-State Kinetics Steady-state drug concentration is determined by: $$C_{ss} = \frac{F \times Dose}{CL_{total} \times \tau}$$ Where: - CL~total~ = CL~renal~ + CL~hepatic~ - In renal failure, CL~renal~ drops precipitously while CL~hepatic~ remains unchanged - Result: CL~total~ falls → C~ss~ rises → both peak and trough accumulate **High-Yield:** Aminoglycosides (gentamicin, tobramycin, amikacin) are **renally eliminated water-soluble drugs** — they are highly sensitive to renal dysfunction. Volume of distribution (Vd) remains relatively constant in renal disease; it is clearance that changes. ### Why Peak and Trough Are Both Elevated | Parameter | Normal Renal Function | CKD Stage 4 (eGFR 25) | |-----------|----------------------|----------------------| | Renal Clearance | ~120 mL/min | ~25 mL/min | | Half-life | 2–3 hours | 24–48 hours | | Peak level | 4–10 µg/mL | Accumulates (12 µg/mL here) | | Trough level | <2 µg/mL | Accumulates (2.5 µg/mL here) | | Dosing strategy | 80 mg Q8H | 80 mg Q24–48H | **Clinical Pearl:** The trough level of 2.5 µg/mL (above the therapeutic <2 µg/mL threshold) indicates inadequate drug elimination between doses — a hallmark of reduced clearance, not altered distribution. ### Correct Management 1. **Reduce the dose** (from 80 mg to ~40–50 mg) OR extend the dosing interval (from Q8H to Q24–48H) 2. **Redose based on serum levels** — therapeutic drug monitoring is essential 3. **Avoid nephrotoxicity** — aminoglycosides are nephrotoxic; high troughs increase risk **Mnemonic:** **RENAL DRUGS** = Renally Eliminated drugs Need Adjustment in renal disease. Gentamicin is the archetype. [cite:KD Tripathi 8e Ch 50]